Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that 90 patients have been randomized in its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC).  This represents the target number of patients required to conduct the pre-planned interim analysis.  The analysis will be conducted when these patients have completed 6 weeks of dosing.
More information on :